Stock AnalizIncyte Corp. INCY
Biotechnology: Commercial Physical & Biological Resarch · data as of November 13, 2026
Incyte Corp. (INCY) is a healthcare company listed in the US with a market value of about $24.7B. In the twelve months to September 30, 2026 it had revenue of $6.0B and net income of $403M, a net margin of 6.7%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 64.3, a price to free cash flow of 36.3, 5-year revenue growth of 14% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 48% below the current price.
Score: 2.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.0B | $5.1B | $4.2B | $3.7B | $3.4B | $3.0B | $2.7B | $2.2B | $1.9B | $1.5B | $1.1B |
| Net income | $403M | $1.3B | $33M | $598M | $341M | $949M | -$296M | $447M | $109M | -$313M | $104M |
| Free cash flow | $680M | — | — | — | $892M | $568M | -$312M | $633M | $263M | -$204M | $184M |
| EPS (diluted) | $1.88 | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | $-1.36 | $2.05 | $0.51 | $-1.53 | $0.54 |
| Net margin | 6.7% | 25.0% | 0.8% | 16.2% | 10.0% | 31.8% | -11.1% | 20.7% | 5.8% | -20.4% | 9.4% |
| ROIC | — | 22.6% | 1.4% | 8.5% | 8.5% | 12.2% | -7.9% | 14.1% | 0.6% | -11.6% | 12.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 24 analysts is $131.50, 9% above the current price; targets range from $100.00 to $157.00; the consensus rating is “Buy”; expected EPS is $3.46 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Incyte’s P/E ratio?
About 64.3, based on the last twelve months of diluted earnings per share (forward P/E about 15.1).
Is Incyte stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 48% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Incyte pay a dividend?
Not currently.
Is Incyte a good stock to buy?
We do not give buy or sell advice. Incyte scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.